Wikipedia talk:WikiProject Pharmacology

From WikiProjectMed
Jump to navigation Jump to search

WikiProject Pharmacology (Rated Project-class)
WikiProject iconThis page is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Project This page does not require a rating on the project's quality scale.

No simufilam article

This drug, while relatively new and not yet approved, has been in the news for a while. Odd that nobody has taken on an article. Whether it works or not is immaterial. It appears to qualify as a subject of interest to Wikipedia.--Quisqualis (talk) 02:29, 20 April 2022 (UTC)Reply[reply]

I created a bare bones article at Simufilam, but I haven't got access to the right sources for fleshing it out. --ἀνυπόδητος (talk) 08:05, 20 April 2022 (UTC)Reply[reply]

Some eyes on the article would be welcome because of repeated IP edits that look very POVy to me. However, I don't have access to the relevant journals, and also quite frankly not the time to handle this. Thanks --ἀνυπόδητος (talk) 19:16, 8 May 2022 (UTC)Reply[reply]

Very COI/POVy editors at the related Cassava Sciences. More eyes needed, semi-protection expires tomorrow. SandyGeorgia (Talk) 02:59, 6 August 2022 (UTC)Reply[reply]

I have attempted some cleanup at Simufilam, which is clearly as plagued by COI/POV editing as was Cassava Sciences. More eyes are needed at both; I have barely scratched the surface of either article; both have been hit by non-neutral IP editing. SandyGeorgia (Talk) 16:46, 6 August 2022 (UTC)Reply[reply]

I could really use some help at both simufilam and Cassava Sciences. There have been two different types of COI editing: 1) puffery to promote the company, and b) smears to tarnish it (per the short-selling issue). Cassava Sciences had been semi-protected twice, and the IPs are finally registering accounts and weighing in on talk (which makes for a lot of work, educating new editors). There is much cleanup needed still. I don't know how drug articles are typically organized, but the company proponents want to include a lot of press releases and primary sources. I also don't know how clinical trials should be organized in drug articles, so wish some Pharm editors would take on the drug article. SandyGeorgia (Talk) 03:27, 17 August 2022 (UTC)Reply[reply]

Featured Article Save Award for Enzyme inhibitor

There is a Featured Article Save Award nomination at Wikipedia talk:Featured article review/Enzyme inhibitor/archive1. Please join the discussion to recognize and celebrate editors who helped assure this article would retain its featured status. SandyGeorgia (Talk) 02:58, 6 August 2022 (UTC)Reply[reply]

Cassava and simufilam

Draft:Precision BioSciences

Hi! Sharing in case this is of interest to anyone here: a draft article about Precision BioSciences, a publicly traded clinical stage gene editing company, is currently under review in the AfC queue. I have a COI here – Precision BioSciences is a client of mine. Happy to answer any questions, and appreciate any time/feedback. Thanks! Mary Gaulke (talk) 22:31, 9 September 2022 (UTC)Reply[reply]

Inclusion of Ivermectin on Protease inhibitor (pharmacology)

Hi there! I'm involved in a dispute on whether Ivermectin should be listed as a 3-chymotrypsin-like protease inhibitor on the page Protease inhibitor (pharmacology). It would be terrific if additional editors could weigh in to help resolve the dispute, and the community here seems like a really good resource. I've added some discussion to Talk:Protease inhibitor (pharmacology), as well. Thanks so much! Asacarny (talk) 04:17, 26 September 2022 (UTC)Reply[reply]